Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Birdshot HLA A29 Uveitis
NCT03871361Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in Birdshot Chorioretinopathy (BCR), sponsored by UZ Leuven. Primary endpoint: Time to recurrence in ≥1 eye at 2 years. Started Apr 2019; status: completed.
02
Drugs
abatacept
03
Conditions
Birdshot Chorioretinopathy (BCR)
Beyond the preview
Go deeper on NCT03871361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871361.